Lasinavir
From Infogalactic: the planetary knowledge core
200px | |
Names | |
---|---|
IUPAC name
tert-butyl N-[(2S,3S,5R)-3-hydroxy-6-[[(2S)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate
|
|
Identifiers | |
175385-62-3 | |
ChemSpider | 408297 |
Jmol 3D model | Interactive image |
PubChem | 464372 |
UNII | 0QGV8237I3 |
|
|
|
|
Properties | |
C35H53N3O9 | |
Molar mass | 659.81 g/mol |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
what is ?) | (|
Infobox references | |
Lasinavir (INN,[1] previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection. It was originally discovered by Novartis at Basel (Switzerland).[2] Its investigation was terminated after Phase I on October 09, 2002.[3]
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ B2 US patent 7348345 B2, James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney, "Nonnucleoside reverse transcriptase inhibitors", issued 2008-08-02
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Pages with broken file links
- Articles without EBI source
- Articles without KEGG source
- Pages using collapsible list with both background and text-align in titlestyle
- Chemical articles using a fixed chemical formula
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Alcohols
- Carboxamides
- Carbamates
- Protease inhibitors
- Antiinfective agent stubs